Leede Financial Has Negative View of TSE:TH FY2026 Earnings

Theratechnologies Inc. (TSE:TH - Free Report) - Leede Financial cut their FY2026 earnings per share estimates for Theratechnologies in a report issued on Monday, April 14th. Leede Financial analyst D. Loe now expects that the company will post earnings of $0.20 per share for the year, down from their prior forecast of $0.21. The consensus estimate for Theratechnologies' current full-year earnings is $0.03 per share. Leede Financial also issued estimates for Theratechnologies' FY2027 earnings at $0.28 EPS.

Other research analysts also recently issued reports about the company. Jones Trading upgraded Theratechnologies from a "hold" rating to a "strong-buy" rating in a research note on Friday, April 11th. Research Capitl upgraded shares of Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.

Theratechnologies Stock Down 2.8 %

Shares of TSE TH traded down C$0.10 during mid-day trading on Tuesday, hitting C$3.48. The company had a trading volume of 159,892 shares, compared to its average volume of 103,808. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of -293.92. The firm has a 50-day simple moving average of C$2.44 and a two-hundred day simple moving average of C$2.21. The company has a market capitalization of C$111.03 million, a PE ratio of -39.39, a price-to-earnings-growth ratio of -8.50 and a beta of 1.73. Theratechnologies has a one year low of C$1.59 and a one year high of C$4.33.

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.